Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 732 Phase 1/2 study in healthy volunteers and patients with thyroid eye disease
2024-514110-12-00Phase 2Authorised
- Sponsor
- Amgen
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of AMG 732 in Graves Orbitopathy (GO) (4 arms), sponsored by Amgen. Primary endpoint: Change from baseline in proptosis. Planned start Oct 2025; status: authorised.
02
Drugs
AMG 732
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2024-514110-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514110-12-00.